Predicting anthracycline benefit: TOP2A and CEP17 - Not only but also

Journal of Clinical Oncology

Volumn 33, Issue 15, 2015, Pages 1680-1687

  Bartlett, John M S ^a,c,e   McConkey, Christopher C ^f   Munro, Alison F ^e   Desmedt, Christine ^j   Dunn, Janet A ^f   Larsimont, Denis P ^j   O'Malley, Frances P ^c   Cameron, David A ^e   Earl, Helena M ^g   Poole, Christopher J ^a,f   Shepherd, Lois E ^c,d   Cardoso, Fatima ^k   Jensen, Maj Britt ^l   Caldas, Carlos ^g   Twelves, Christopher J ^h   Rea, Daniel W ⁱ   Ejlertsen, Bent ^l   Leo, Angelo Di ^m   Pritchard, Kathleen I ^b  

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Clinical Trials Group   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g UNIVERSITY OF WARWICK   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^j UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^k Champalimaud Cancer Centre   (Portugal)

^l University of Copenhagen   (Denmark)

^m Hospital of Prato   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; FLUORESCENT DYE; GENETIC MARKER; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CEP17 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DUPLICATION; HUMAN; HUMAN TISSUE; ONCOGENE NEU; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TOP2A GENE; TREATMENT RESPONSE; CENTROMERE; CHEMISTRY; CHROMOSOME 17; DISEASE FREE SURVIVAL; GENETIC MARKER; GENETICS; META ANALYSIS; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTROMERE; CHROMOSOMES, HUMAN, PAIR 17; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FLUORESCENT DYES; FLUOROURACIL; GENETIC MARKERS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84933575890     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.7869     Document Type: Article

References (38)

1. Bartlett JM, Ellis IO, Dowsett M, et al: Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol 25:4423-4430, 2007
2. Pritchard KI, Shepherd LE, O'Malley FP, et al: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111, 2006
3. Knoop AS, Knudsen H, Balslev E, et al: Retrospective analysis of topoismerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483-7490, 2005
4. Ross JS, Fletcher JA, Bloom KJ, et al: Targeted therapy in breast cancer: The HER-2/neu gene and protein. Mol Cell Proteomics 3:379-398, 2004
5. Järvinen TA, Kononen J, Peltohuikko M, et al: Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 148: 2073-2082, 1996
6. Watters AD, Going JJ, Cooke TG, et al: Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 77:109-114, 2003
7. Bartlett JMS, Campbell FM, Mallon EA: Determination of HER2 amplification by in situ hybridization: When should chromosome 17 also be determined? Am J Clin Pathol 130:920-926, 2008
8. Bartlett JM, Munro AF, Dunn JA, et al: Predictive markers of anthracycline benefit: A prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 11: 266-274, 2010
9. Di Leo A, Desmedt C, Bartlett JM, et al: HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: A meta-analysis of individual patient data. Lancet Oncol 12:1134-1142, 2011
10. O'Malley FP, Chia S, Tu D, et al: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101:644-650, 2009
11. Munro AF, Cameron DA, Bartlett JM: Targeting anthracyclines in early breast cancer: New candidate predictive biomarkers emerge. Oncogene 29:5231-5240, 2010
12. Pritchard K, Munro A, O'Malley FP, et al: Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: Evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 trial. Breast Cancer Res Treat 131:541-551, 2012
13. Yeh IT, Martin MA, Robetorye RS, et al: Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 22:1169-1175, 2009
14. Poole CJ, Earl HM, Hiller L, et al: Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 355:1851-1862, 2006
15. Levine MN, Pritchard KI, Bramwell VH, et al: Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group trial MA5. J Clin Oncol 23:5166-5170, 2005
16. Di Leo A, Gancberg D, Larsimont D, et al: HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8:1107-1116, 2002
17. Bartlett JM, Munro A, O'Malley FP, et al: Duplication of chromosome 17 CEP predicts for anthracycline benefit: Evidence from an international meta-analysis of 4 adjuvant breast cancer trials for the HER2/TOP2A meta-analysis study group. EJC Suppl 8:121, 2010
18. Ma Y, Lespagnard L, Durbecq V, et al: Polysomy 17 in HER-2/neu status elaboration in breast cancer: Effect on daily practice. Clin Cancer Res 11:4393-4399, 2005
19. Piccart MJ, Di Leo A, Beauduin M, et al: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19:3103-3110, 2001
20. Ejlertsen B, Mouridsen HT, Jensen MB, et al: Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 43:877-884, 2007
21. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumour MARKer Prognostic Studies (REMARK). Br J Cancer 93:387-391, 2005
22. Fraser JA, Reeves JR, Stanton PD, et al: A role for BRCA1 in sporadic breast cancer. Br J Cancer 88:1263-1270, 2003
23. Fraser M, Leung BM, Yan X, et al: p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 63:7081-7088, 2003
24. McClendon AK, Osheroff N: DNA topoisomerase II, genotoxicity, and cancer. Mutat Res 623:83-97, 2007
25. Olivier M, Petitjean A, Marcel V, et al: Recent advances in p53 research: An interdisciplinary perspective. Cancer Gene Ther 16:1-12, 2009
26. Greenberg RA: Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network. Chromosoma 117:305-317, 2008
27. Arriola E, Marchio C, Tan DS, et al: Genomic analysis of the HER2//TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 88:491-503, 2008
28. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
29. Del Mastro L, Bruzzi P, Nicolo G, et al: HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br J Cancer 93:7-14, 2005
30. Di Leo A, Biganzoli L, Claudino W, et al: Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: Ready for the primetime? Eur J Cancer 44:2791-2798, 2008
31. Di Leo A, Chan S, Paesmans M, et al: HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 86:197-206, 2004
32. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node- positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998
33. Paik S, Bryant J, Tan-Chiu E, et al: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-15. J Natl Cancer Inst 92:1991-1998, 2000
34. Pritchard KI, Messersmith H, Elavathil L, et al: HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26:736-744, 2008
35. Bartlett JMS, Munro A, Dunn JA, et al: Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: Emerging evidence from the UK NEAT adjuvant breast cancer trial. Cancer Res 69:74S, 2009
36. Bartlett JM, Munro A, Cameron DA, et al: Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 26:5027-5035, 2008
37. Mueller RE, Parkes RK, Andrulis I, et al: Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 39:288-297, 2004
38. Press MF, Sauter G, Buyse M, et al: Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 29:859-867, 2011